Furthermore, our demonstration of a novel synthetic interaction between MYC activation and CLK inhibition provides a better understanding of the functions of the MYC proto‐oncogene and CLK, and highlights the specific clinical application of the CLK inhibitor for MYC‐activated cancers. Here, CLK1 is linked to cancer.